Skip to main content

Table 3 Association of clinical, pathological and genotypic parameters with radiological response at 4th month of letrozole administration.

From: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Parameters Responders (%) Non-responders (%) p
Age (years)    
   ≤ 78.3 19 (54.3) 29 (48.3) 0.576
   > 78.3 16 (45.7) 31 (51.7)  
Histological diagnosis    
   IDC 25 (71.4) 42 (70.0) 0.843
   ILC 5 (14.3) 11 (18.3)  
   Others 5 (14.3) 7 (7.4)  
Histological grade    
   I 13 (61.9) 16 (51.6) 0.606
   II 6 (28.6) 13 (41.9)  
   III 2 (9.5) 2 (6.5)  
Tumor size (T)    
   T2 31 (88.6) 45 (75.0) 0.111
   T3-T4 4 (11.4) 15 (25.0)  
Lymph node involvement (N)    
   NO 28 (80.0) 48 (80.0) 1.000
   N1-2 7 (20.0) 12 (20.0)  
Stage    0.546
   IIa 26 (74.3) 39 (65.5)  
   IIb 7 (20.0) 13 (21.7)  
   IIIa-IIIb 2 (5.7) 8 (13.3)  
ER    
   ≤ 40% 3 (8.6) 10 (16.7) 0.268
   > 40% 32 (91.4) 50 (83.3)  
PgR    
   ≤ 40% 15 (42.9) 31 (51.7) 0.407
   > 40% 20 (57.1) 29 (48.3)  
HR    
   ≤ 40% 2 (5.7) 8 (13.3) 0.243
   > 40% 33 (94.3) 52 (86.7)  
HER2    
   0, + 21 (60.0) 42 (70.0) 0.320
   ++, +++ 14 (40.0) 18 (30.0)  
Ki67    
   Negative 15 (55.6) 25 (55.6) 1.000
   Positive 12 (44.4) 20 (44.4)  
rs10046    
   GG 6 (17.1) 9 (15.0) 0.782
   AG/AA 29 (82.9) 15 (85.0)  
rs4646    
   CC 26 (74.3) 31 (51.7) 0.030
   AC/AA 9 (25.7) 29 (48.3)